期刊文献+

探讨高龄乳腺癌患者术后早期应用多西他赛辅助化疗的安全性 被引量:3

Discussion elderly breast cancer patients after early application of docetaxel adjuvant chemotherapy weekly safety
下载PDF
导出
摘要 目的:探讨高龄乳腺癌患者术后早期应用多西他赛辅助化疗的安全性。方法:将2010年2月~2012年2月于我院接受治疗的60例年龄超过70岁的乳腺癌患者作为研究对象,随机将其分为对照组与观察组各30例,对观察组患者于术后3d开始应用多西他赛每周辅助化疗方案,对照组患者术后2周开始给予相同的辅助化疗方案,对比观察两组化疗效果。结果:两组患者在接受化疗治疗后,血清内白细胞水平均得到不同程度的下降,治疗六周后观察组白细胞水平为[(3.59±0.91)×109/L],下降趋势较对照组明显,差异显著(t=9.365,P〈0.05);观察组术后创口愈合时间为(10.31±2.56)d,对照组为(10.51±3.11)d,两组患者术后创口愈合时间对比并无显著差异(t=0.157,P〉0.05)。结论:对高龄乳腺癌术后治疗宜选用早期多西他赛每周化疗方案,在降低肿瘤复发可能性的同时能够提高治疗效果,提升患者的生存质量,值得推广。 Objective:To investigate the application and analysis of early postoperative docetaxel chemotherapy safety of elderly breast cancer patients. Methods February 2010 to February 2012 in our hospital treated 60 patients aged over 70 years of age for the study of breast cancer patients were randomly divided into a control group and the observation group(30 cases) of patients in the observation group 3d begin after application docetaxel weekly adjuvant chemotherapy,patients in the control group will be held two weeks after the start of adjuvant chemotherapy given the same treatment,the effect of chemotherapy were observed in comparison. After the results of the two groups of patients undergoing chemotherapy treatment,serum white blood cell levels were obtained varying degrees of decline,after six weeks of treatment groups were observed for white blood cell levels [(3.59±0.91)×109/L],a downward trend compared with the control group of patients and words more obvious contrast between the two groups were significantly different(t =9.365,P 0.05);observation group postoperative wound healing time was(10.31±2.56)d,the patients in the control group(10.51±3.11)d,two groups of patients Comparison of postoperative wound healing time there was no significant difference(t=0.157,P0.05). Conclusions Postoperative treatment of elderly patients with early breast cancer should use docetaxel weekly chemotherapy in reducing the likelihood of tumor recurrence at the same time be able to improve the therapeutic effect,enhance the quality of life of patients,it is worth promoting.
作者 罗超元
出处 《北方药学》 2015年第8期140-142,共3页 Journal of North Pharmacy
关键词 高龄 乳腺癌 化疗 多西他赛 Elderly Breast cancer Chemotherapy Docetaxel
  • 相关文献

参考文献11

二级参考文献74

  • 1应红艳,白春梅,管梅,陈书长.老年乳腺癌患者的临床病理特点及治疗影响因素[J].中国医学科学院学报,2010,32(4):398-402. 被引量:25
  • 2任洪波,王琦,李少林,黄碧有.术前化疗结合放疗治疗炎性乳腺癌疗效分析[J].中国肿瘤临床,2006,33(7):384-385. 被引量:7
  • 3蔡海峰,赵刚,潘惠承.新辅助化疗在隐匿性乳腺癌中的应用[J].中国综合临床,2006,22(6):538-539. 被引量:4
  • 4凌瑞,王俊义,王为忠,李孟彬.胃癌患者围手术期IL-2及sIL-2R的动态研究[J].细胞与分子免疫学杂志,1997,13(1):13-15. 被引量:8
  • 5Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase Ⅱ trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer [J]. Clin Cancer Res, 2004, 10(20): 6764- 6769.
  • 6DCTD, NCI, NIH, et al. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0, December 12, 2003.
  • 7Amat S, Bougnoux P, Penaulu-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate [ J ] . Br J Cancer, 2003, 88(9): 1339-1345.
  • 8Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer [J]. J Clin Oncol, 1999, 17(2): 485-493.
  • 9Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine(xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines [ J ] . Br J Cancer, 2002, 86(9): 1367-1372.
  • 10Lueck H, Minckwitz GV, Du Bios A, et al. Epirubicin/ paclitaxel(EP) vs. capecitabine/paclitaxel(XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase Ⅲ study of the AGO breast cancer study group [ J ] . J Clin Oncol, 2006, 24(18Suppl): 517.

共引文献86

同被引文献30

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部